AbbVie upgraded to buy at Societe Generale; sees 48% upside
Societe Generale has upgraded$AbbVie (ABBV.US)$to buy from hold on what it views as better than expected execution of its immuno-inflammation and aesthetics businesses.
The firm also raised its priced target from $111 to $172 (~48% upside).
Analyst Justin Smith said that AbbVie has taken over from Bristol-Myers Squibb (BMY +1.4%) as his preferred value call in the global large cap pharma space.
Following AbbVie's Q3 earnings results, Smith has "full conviction" in the company's long-term guidance for the Allergan aesthetics franchise.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
tk0TEeeFdX
Rann New
:
And it sb below normal as abbv will have 2 years of falling/stagnant growth due to Humira. Once past that, then pe multiple can expand as long as pipeline is productive. Growth is great right now though and that sb a mitigating factor. Is a top 5 holding with 1,600 shares.
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Austin ONeill : Long ABBV
Wyatt lincoln : As much as I like ABBV, methinks someone is a wee bit optimistic on the price target.
Sacai Luis Wyatt lincoln : I’m of the same opinion, that number is astounding.
Rann New Sacai Luis : Current fwd. PE is 9.16!
sPhCqxPcWZ Rann New : Yeau but the stagnated growth (or perceived stagnated growth) is why it doesn't trade at like 12-20 FWD P/E.
tk0TEeeFdX Rann New : And it sb below normal as abbv will have 2 years of falling/stagnant growth due to Humira. Once past that, then pe multiple can expand as long as pipeline is productive.
Growth is great right now though and that sb a mitigating factor. Is a top 5 holding with 1,600 shares.
TpdPfbWje4 : GO ABBV!
4W7smhOHmW : BMY has better valuation and pipeline.
sbSeUJwoWL 4W7smhOHmW : Absolutely ridiculous. ABBV better company more innovative and better dividend growth
Leung A sbSeUJwoWL : I actually don‘t care. I own both … and AMGN. Couldn‘t be happier …